Literature DB >> 8199353

Signal transduction by the PDGF receptors.

L Claesson-Welsh1.   

Abstract

The three isoforms of PDGF bind with different affinities to two related tyrosine kinase receptors, denoted the PDGF alpha- and beta-receptors. Ligand binding induces receptor dimerization, creating receptor homo- or heterodimers. Dimerization is accompanied by, and might be a prerequisite for, receptor autophosphorylation and kinase activation. Receptor autophosphorylation serves to regulate the kinase activity and to create binding sites on the receptor molecule for downstream signalling components. The activities of the signalling components are ultimately manifested as specific biological responses. All the currently described PDGF receptor-binding components, e.g. phospholipase C-gamma, members of the src family of cytoplasmic tyrosine kinases, the rasGT-Pase activating protein and p85, the regulatory subunit of phosphatidylinositol 3' kinase, contain a conserved src homology 2-domain, through which the association with the receptor takes place. The receptor-binding components appear to either possess an intrinsic enzymatic activity, or they function as adaptors, which may complex with catalytically active components. For most receptor-binding components, there is insufficient understanding of how binding to the receptor affects the catalytic function. Certain of these components become tyrosine-phosphorylated, i.e. they are substrates for the receptor tyrosine kinase. Moreover, the change in subcellular localization, which most of the receptor binding components undergo in conjunction with receptor binding, could play a critical role. The current efforts of many laboratories are aimed at delineating different PDGF receptor signal transduction pathways and what roles the different receptor-binding components play in the establishment of these pathways.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199353     DOI: 10.1016/0955-2235(94)90016-7

Source DB:  PubMed          Journal:  Prog Growth Factor Res        ISSN: 0955-2235


  16 in total

Review 1.  Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs.

Authors:  I F Dunn; O Heese; P M Black
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

2.  Human platelet inhibition of Toxoplasma gondii growth.

Authors:  B F Chumpitazi; J Simon; B Polack; F Peyron; S Picot; J Ricard; P Ambroise-Thomas
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

3.  Gene expression profiling defined pathways correlated with fibroblast cell proliferation induced by Opisthorchis viverrini excretory/secretory product.

Authors:  Chanitra Thuwajit; Peti Thuwajit; Kazuhiko Uchida; Daoyot Daorueang; Sasithorn Kaewkes; Sopit Wongkham; Masanao Miwa
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

4.  A requirement for fibroblast growth factor in regulation of skeletal muscle growth and differentiation cannot be replaced by activation of platelet-derived growth factor signaling pathways.

Authors:  A J Kudla; M L John; D F Bowen-Pope; B Rainish; B B Olwin
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

5.  Myc is an essential negative regulator of platelet-derived growth factor beta receptor expression.

Authors:  S K Oster; W W Marhin; C Asker; L M Facchini; P A Dion; K Funa; M Post; J M Sedivy; L Z Penn
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

6.  Tyr-716 in the platelet-derived growth factor beta-receptor kinase insert is involved in GRB2 binding and Ras activation.

Authors:  A K Arvidsson; E Rupp; E Nånberg; J Downward; L Rönnstrand; S Wennström; J Schlessinger; C H Heldin; L Claesson-Welsh
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

7.  Human cytomegalovirus downregulates expression of receptors for platelet-derived growth factor by smooth muscle cells.

Authors:  Sara Gredmark; Klas Strååt; Mohammed Homman-Loudiyi; Katja Kannisto; Cecilia Söderberg-Nauclér
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

8.  Radical decisions in cancer: redox control of cell growth and death.

Authors:  Rosa M Sainz; Felipe Lombo; Juan C Mayo
Journal:  Cancers (Basel)       Date:  2012-04-25       Impact factor: 6.639

9.  E5 oncoprotein retained in the endoplasmic reticulum/cis Golgi still induces PDGF receptor autophosphorylation but does not transform cells.

Authors:  J Sparkowski; J Anders; R Schlegel
Journal:  EMBO J       Date:  1995-07-03       Impact factor: 11.598

10.  PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Authors:  Daniela Laimer; Helmut Dolznig; Karoline Kollmann; Paul W Vesely; Michaela Schlederer; Olaf Merkel; Ana-Iris Schiefer; Melanie R Hassler; Susi Heider; Lena Amenitsch; Christiane Thallinger; Philipp B Staber; Ingrid Simonitsch-Klupp; Matthias Artaker; Sabine Lagger; Suzanne D Turner; Stefano Pileri; Pier Paolo Piccaluga; Peter Valent; Katia Messana; Indira Landra; Thomas Weichhart; Sylvia Knapp; Medhat Shehata; Maria Todaro; Veronika Sexl; Gerald Höfler; Roberto Piva; Enzo Medico; Bruce A Ruggeri; Mangeng Cheng; Robert Eferl; Gerda Egger; Josef M Penninger; Ulrich Jaeger; Richard Moriggl; Giorgio Inghirami; Lukas Kenner
Journal:  Nat Med       Date:  2012-10-14       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.